The Addressable Market
The addressable market for cholestatic chronic liver diseases, PBC and PSC, is not perceived to be very lucrative relative to that of NASH. However, therapeutics for PBC and PSC do have high pricing power due to their orphan designation status. Notably, the overall addressable market for PSC currently estimated at 60,000 in the US and Europe is expected to be significantly higher in future years due to increased awareness and diagnosis of chronic liver diseases in Asia. Asian countries, including China and India, have a total population estimated at 4 billion individuals.